v3.26.1
Leases
3 Months Ended
Mar. 31, 2026
Leases [Abstract]  
Leases Leases
The Company leases facilities in Ann Arbor, Michigan, Cambridge, Massachusetts and Burlington, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases certain equipment.

On January 28, 2022, the Company entered into a lease agreement (as amended, the “Burlington Lease”) to lease approximately 126,000 square feet of manufacturing, laboratory and office space in Burlington, Massachusetts. The Burlington facility is complete, and the Company is currently utilizing the facility’s office space. In March 2026, the Company received FDA approval to begin MACI commercial manufacturing at the Burlington facility, and a portion of the tenant improvements to the manufacturing suites and related equipment related to MACI manufacturing were placed in service following the FDA approval. The Company has begun transitioning the Burlington facility’s manufacturing component into the primary manufacturing facility for MACI. The Company intends that the Burlington facility’s manufacturing component will eventually also become the primary manufacturing facility for Epicel, upon FDA qualification for Epicel manufacturing.

For the three months ended March 31, 2026 and 2025, lease expense of less than $0.1 million and $0.2 million, respectively, was recorded related to short-term leases. For each of the three months ended March 31, 2026 and 2025, the Company recognized $3.0 million of operating lease expense. For each of the three months ended March 31, 2026 and 2025, the Company recognized less than $0.1 million of financing lease expense.

Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2026December 31, 2025
Assets
OperatingRight-of-use assets$63,409 $64,774 
FinanceProperty and equipment, net686 686 
Total leased assets$64,095 $65,460 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$14,063 $13,969 
FinanceOther current liabilities116 116 
Non-current
OperatingOperating lease liabilities$80,362 $82,284 
FinanceOther long-term liabilities501 522 
Total leased liabilities$95,042 $96,891 
Leases Leases
The Company leases facilities in Ann Arbor, Michigan, Cambridge, Massachusetts and Burlington, Massachusetts. The Ann Arbor facility includes office space, and the Cambridge facility includes clean rooms, laboratories for MACI and Epicel manufacturing and office space. The Company also leases certain equipment.

On January 28, 2022, the Company entered into a lease agreement (as amended, the “Burlington Lease”) to lease approximately 126,000 square feet of manufacturing, laboratory and office space in Burlington, Massachusetts. The Burlington facility is complete, and the Company is currently utilizing the facility’s office space. In March 2026, the Company received FDA approval to begin MACI commercial manufacturing at the Burlington facility, and a portion of the tenant improvements to the manufacturing suites and related equipment related to MACI manufacturing were placed in service following the FDA approval. The Company has begun transitioning the Burlington facility’s manufacturing component into the primary manufacturing facility for MACI. The Company intends that the Burlington facility’s manufacturing component will eventually also become the primary manufacturing facility for Epicel, upon FDA qualification for Epicel manufacturing.

For the three months ended March 31, 2026 and 2025, lease expense of less than $0.1 million and $0.2 million, respectively, was recorded related to short-term leases. For each of the three months ended March 31, 2026 and 2025, the Company recognized $3.0 million of operating lease expense. For each of the three months ended March 31, 2026 and 2025, the Company recognized less than $0.1 million of financing lease expense.

Operating and finance lease assets and liabilities are as follows:

(In thousands)ClassificationMarch 31, 2026December 31, 2025
Assets
OperatingRight-of-use assets$63,409 $64,774 
FinanceProperty and equipment, net686 686 
Total leased assets$64,095 $65,460 
Liabilities
Current
OperatingCurrent portion of operating lease liabilities$14,063 $13,969 
FinanceOther current liabilities116 116 
Non-current
OperatingOperating lease liabilities$80,362 $82,284 
FinanceOther long-term liabilities501 522 
Total leased liabilities$95,042 $96,891